 |
市場調查報告書
商品編碼
1349857
缺血再灌流傷害治療藥市場:各治療法，傷害，各終端用戶，各地區- 規模，佔有率，展望，機會分析，2023年～2030年Ischemia Reperfusion Injury Therapeutics Market, By Treatment, By Injury, By End User, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
價格
簡介目錄
預估 2023 年全球缺血再灌注傷害治療藥物市場規模為 20.6 億美元，預測期內（2023-2030 年）複合年增長率為 6%。
| 報告範圍 | 報告詳細資料 | ||
|---|---|---|---|
| 基準年 | 2022 | 2023 年市場規模 | 20.6億美元 |
| 過去的資料 | 2018年至2021年 | 預測期間 | 2023-2030 |
| 預測 2023-2030 年複合年增長率： | 6.00% | 2030年價值預測 | 30.9億美元 |
缺血再灌注損傷（IRI），也稱為復氧損傷，是在一段時間缺氧（缺血）後血液供應恢復到組織（再灌注）時發生的組織損傷。缺血性損傷的症狀包括心搏過緩、頭痛、高血壓和抽搐。缺血再灌注傷害伴隨心肌冬眠、急性心臟衰竭、腦功能障礙、胃腸功能障礙、全身性發炎反應症候群、多重器官功能障礙症候群等嚴重臨床症狀。缺血再灌注傷害是一種嚴重的醫學病症，為醫師帶來了重要的治療挑戰。
市場動態
主要市場參與者增加治療再灌注傷害患者的研發活動預計將在預測期內推動市場成長。例如，2022年5月31日，製藥公司GNT Pharma報告Nelonemdaz正處於I期臨床試驗。Neronemdaz (Neu2000) 正在開發用於治療急性缺血性中風、創傷性腦損傷、創傷性脊髓損傷、急性心肌梗塞 (AMI)、燒傷和腦梗塞。
此外，2021年9月，製藥公司GNT Pharma申請的臨床試驗許可（IND）已獲得批准。此次 IND 批准是基於 GNT Pharma 之前的 II 期研究的積極結果。這項 III 期研究的結果對於證明 neronemdaz 作為急性缺血性中風的有效治療方法的治療潛力非常重要。
本調查的主要特徵
- 本報告提供以2022年為基準年的預測期間（2023-2030 年）之全球缺血再灌流傷害治療藥市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球缺血再灌流傷害治療藥市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球缺血再灌流傷害治療藥市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球缺血再灌流傷害治療藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱
第2章 市場概況
- 報告概要
- 市場定義和範圍
- 摘要整理
- Coherent Opportunity Map(COM)
第3章 市場動態，法規，趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機會
- 影響分析
- 最近的產品銷售
- 流行病學
- 合併，收購，聯盟
- 法規情勢
- 主要的發展
- PEST分析
- 夥伴關係方案
- 品牌和價格分析
- 分銷商的形勢
- 波特分析
- 技術的進步
- 主要的發展
- 市場趨勢
- 各收益的主要企業
第4章 缺血再灌流傷害治療藥的全球市場:COVID-19影響分析
- 經濟影響
- COVID-19流行病學
- 供需的影響
第5章 缺血再灌流傷害治療藥的全球市場:各治療法，2018年～2030年
- 藥物療法
- 藥用天然氣(氣體)
- 其他(維他命療法等)
第6章 缺血再灌流傷害治療藥的全球市場:傷害各類型，2018年～2030年
- 心臟損傷
- 腎臟損傷
- 腸損傷
- 其他
第7章 缺血再灌流傷害治療藥的全球市場:各終端用戶，2018年～2030年
- 醫院
- 專門診所
- 門診病人手術中心
- 其他(學術研究機關等)
第8章 缺血再灌流傷害治療藥的全球市場:各地區，2018年～2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情形
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
第10章 章節
- 調查手法
- 關於出版社
簡介目錄
Product Code: CMI4105
The global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 2.06 Bn in 2023 and is expected to exhibit a CAGR of 6% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.06 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 6.00% | 2030 Value Projection: | US$ 3.09 Bn |
Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.
Market Dynamics
Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.
Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma's earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.
Key features of the study:
- This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global medical imaging equipment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market
Detailed Segmentation:
- Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
- Drug Therapy
- Medicated Gas
- Others (Vitamin Therapy and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury (Brain Injuries and Among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others(Academic and Research Institutes and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Injury Type
- Market Snapshot, By End user
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Top Market Players by Revenue
4. Global Ischemia Reperfusion Injury Therapeutics Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Medicated Gas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Others (Vitamin Therapy and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
6. Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Heart Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Intestine Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
7. Global Ischemia Reperfusion Injury Therapeutics Market, By End user, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Others (Academic and Research Institutes and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
8. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2018-2030, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018- 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Revive Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
10. Section
- Research Methodology
- About Us
